â– LECTURE OVERVIEW: Acute Rheumatic Fever (ARF) is an autoimmune, post-infectious inflammatory sequela triggered selectively by Streptococcus pyogenes (Group A Beta-Hemolytic Streptococcus, GAS) pharyngitis.
â– IMMUNOPATHOGENIC DETAILS:
1. M Protein (Antiphagocytic): S. pyogenes expresses M Protein, a coiled-coil alpha-helical protein that projects from the cell membrane, preventing phagocytosis by binding fibrinogen and inhibiting complement.
2. Epitopic Mimicry: The structural epitopes of M Protein are highly homologous to human coiled-coil proteins, specifically alpha-myosin and sarcolemma proteins in cardiac tissue, as well as joint and brain antigens.
3. Trans-Activation of B-Cells: The host immune system mounts a vigorous humoral response against the streptococcal M antigen, generating Anti-M antibodies.
4. Autoimmune Damage: These cross-react with cardiac self-antigens, activating the classical complement cascade and recruiting macrophages to healthy cardiac tissue, causing myocarditis, endocarditis, and pericarditis (pancarditis).
â– BIOCHEMICAL MECHANISMS:
At the molecular level, enzyme kinetics govern reaction rates. Competitive inhibitors raise apparent Michaelis constants without changing maximum speed, whereas noncompetitive inhibitors decrease maximum speed directly.
â– SECONDARY PREVENTION METRICS:
Implementing long-term dietary adaptations, physical therapy, and compliance aids reduces the rate of recurring acute crises by more than half.
[HY-BOARD-1230]
🌟 Dynamic Clinical Key:
ARF develops 2-4 weeks after untreated streptococcal pharyngitis (never skin infections/impetigo). Diagnosed via the Jones criteria (joints arthritis, heart carditis, subcutaneous nodules, erythema marginatum, Sydenham chorea). Early treatment of GAS with Penicillin completely prevents ARF. Focus on rate-limiting regulatory steps for pharmacological design. Patient education regarding warning signs and therapy adherence is the cornerstone of secondary prevention.